There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Antibe Therapeutics (ATBPF), Cortexyme (CRTX) and Immunovant (IMVT) with bullish sentiments.
Antibe Therapeutics (ATBPF)
In a report issued on February 12, Stefan Quenneville from Echelon Wealth Partners reiterated a Buy rating on Antibe Therapeutics, with a price target of C$16.00. The company’s shares closed last Monday at $4.59.
Quenneville has an average return of 27.6% when recommending Antibe Therapeutics.
According to TipRanks.com, Quenneville is ranked #3742 out of 7329 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Antibe Therapeutics with a $13.59 average price target, which is a 177.3% upside from current levels. In a report issued on February 9, Canaccord Genuity also maintained a Buy rating on the stock with a C$16.50 price target.
See today’s analyst top recommended stocks >>
Cortexyme (CRTX)
LifeSci Capital analyst David Sherman reiterated a Buy rating on Cortexyme on February 16 and set a price target of $190.00. The company’s shares closed last Monday at $31.83, close to its 52-week low of $26.66.
According to TipRanks.com, Sherman is ranked #7016 out of 7329 analysts.
Currently, the analyst consensus on Cortexyme is a Moderate Buy with an average price target of $79.00, which is a 142.3% upside from current levels. In a report issued on February 16, H.C. Wainwright also maintained a Buy rating on the stock with a $76.00 price target.
Immunovant (IMVT)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant on February 16 and set a price target of $48.00. The company’s shares closed last Monday at $17.01.
According to TipRanks.com, Slutsky is a 3-star analyst with an average return of 11.6% and a 52.9% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics, Catalyst Biosciences, and Cogent Biosciences.
Currently, the analyst consensus on Immunovant is a Strong Buy with an average price target of $38.33, representing an 112.4% upside. In a report issued on February 2, Stifel Nicolaus also assigned a Buy rating to the stock with a $33.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
